Olorofim - F2G
Alternative Names: F-901318Latest Information Update: 27 Mar 2025
At a glance
- Originator F2G
- Class Antifungals; Piperazines; Pyrimidines; Pyrroles; Small molecules
- Mechanism of Action Dihydroorotate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Mycoses
- Phase III Invasive bronchopulmonary aspergillosis
- Phase II Coccidioidomycosis
Most Recent Events
- 27 Apr 2024 Antimicrobial data from preclinical studies in Mycoses presented at the 34th Congress of the European Society of Clinical Microbiology and Infectious (ESCMID-2024)
- 27 Apr 2024 Antimicrobial data from preclinical studies in Mycoses presented at the 34th Congress of the European Society of Clinical Microbiology and Infectious (ESCMID-2024)
- 21 Oct 2023 Efficacy data from the phase II FORMULA-OLS trial in Mycoses released by F2G